Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT05806515 trial: what clinicians have said so far
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- NCT05806515 ↗
- Recruiting
- SWOG Cancer Research Network
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05806515 (carboplatin in localized high-risk prostate cancer with germline BRCA1/2 mutations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05806515 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built |
The trial
ClinicalTrials.gov- Official title
- S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer With Germline BRCA1/2 Mutations
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Prostate Adenocarcinoma; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection; Carboplatin; Chest Radiography; Computed Tomography; Magnetic Resonance Imaging; PSMA PET Scan; Surgical Procedure
- Arms
- Treatment (carboplatin) · Experimental
- Enrollment
- 44 (estimated)
- Primary outcomes
- Pathologic complete response after neoadjuvant carboplatin
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Mar 1, 2024
- Primary completion
- Jul 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05806515 · updated Jan 29, 2026